Welcome to the ValueWiki MYLAN LABS INC (MYL) article! Register for free or click the "edit" link to contribute!    

MYLAN LABS INC (MYL)

From ValueWiki

Jump to: navigation, search
This summary section needs content! Click Here to begin writing.
Have a question about MYLAN LABS INC? Ask it on the Message Board or Chat Room
Visit the Apple, Inc. page for an example of a complete article.

Contents

Today 5d 3m 6m 1y 2y 5y Max



Funds w/ MYL: 38
Rank: 314 / 351



Company Analysis

You can add your own information here - just click the blue edit tab. Or view examples at the Start a new article page.

The edit window has shortcut and help links if you need them.[1] Be bold!

News Feed

12/02/08 11:12 am Generic drug group spent $506,976 lobbying in 3Q (AP)
12/02/08 8:12 am Mylan, Novartis settle patent dispute on Femara (AP)
12/02/08 7:12 am UPDATE - Novartis, Mylan agree on Femara generic (at Reuters)
12/02/08 7:12 am Mylan settles with Novartis over its breast-cancer drug (at MarketWatch)
12/02/08 7:12 am InPlay: Mylan announces settlement agreement with Novartis related to Femara first-to-file opportunity (Briefing.com)
12/02/08 7:12 am Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity (PR Newswire)
12/01/08 9:12 am Companies sue Mylan over generic version of Amrix (AP)
12/01/08 8:12 am Mylan Confirms First-to-File Patent Challenge Relating to AMRIX(R) (PR Newswire)
11/29/08 8:11 am Cephalon sues to defend Amrix patent (at bizjournals.com)
11/28/08 5:11 am Mylan on the Comeback Trail (at Seeking Alpha)
More News...

Risks

This section needs content! Click the blue edit link (to the right) to contribute.

Research Links

MYLAN LABS INC Snapshot
MYLAN LABS INC Leadership
MYLAN LABS INC Fundamentals
MYLAN LABS INC Technical Analysis
MYLAN LABS INC Message Boards

Options

Notes

  1. This is a sample reference.
Personal tools